E N D Presentation Transcript GLP-1 Agonists and Cardiovascular Health Alan Mathis PharmD Candidate 2013 www.DIABETESINCONTROL.COM Part 2 of 2 Change in Triglycerides and HDL-C as Function of Weight-Change Quartile at 82 Weeks Effects of GLP-1 agonists on inflammatory markers GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) E-selectin was not significantly reduced C-reactive protein has also been associated with increased cardiovascular disease Patients treated with exenatide showed marked decrease in c-reactive protein levels after an 82-week study (from 3.21mg/dL to 1.35 mg/dL) Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbAlc, and body weight in patients with type 2 diabetes mellitus
Household Mold, Pesticide Use, and Childhood Asthma: A Nationwide Study in the U.S. International Journal of Hygiene and Environmental Health, vol
Pressure effects on in vivo microbial processes
Mannitol 200 mg *
However, DBS might also increase and regularize the output of the stimulated region by activating local axonsthis is certainly an appealing hypothesis in cerebellar disorders since much of electrophysiological defects could stem from changes in the firing regularity of the cerebellar nuclear neurons
Liver health
